LXRX
$3.20
Lexicon Pharmaceutcl
($.06)
(1.84%)
LXRX
Earnings Whisper ®
N/A
3rd Quarter September 2019
Consensus:  $1.31
Revenue:  $13.06 Mil
Thursday
Oct 31
7:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when LXRX reports earnings?
Beat
Meet
Miss

Where is LXRX's stock price going from here?
Up
Flat
Down
Stock chart of LXRX
Analysts
Summary of analysts' recommendations for LXRX
Score
Grade
Pivots
Resistance
$3.47
$3.39
$3.30

$3.22

Support
$3.13
$3.05
$2.96
Tweet
Growth
Description
Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology. Lexicon has invented high-throughput gene trapping technology to discover thousands of genes and expand its OmniBank library of tens of thousands of mouse clones. The Company uses an integrated platform of functional genomic technologies to accelerate large-scale analysis of mammalian gene function for drug discovery.
Peers
BiogenGilead SciencesBluebird BioAmgenNeurocrine BiosciencesSeattle GeneticsQiagen N.V.RepligenBioCryst PharmaceuticalsNovavax